Dexcom Inc. (DXCM) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dexcom Inc. (DXCM:NASDAQ), powered by AI.

Current Price
$75.37
P/E Ratio
35.2
Market Cap
29.4B
Sector
Healthcare
What is the Dexcom Inc. stock price forecast?

Dexcom Inc. is currently trading at $75.37. View real-time AI analysis on Alpha Lenz.

What is Dexcom Inc. insider trading activity?

View the latest insider trading data for Dexcom Inc. on Alpha Lenz.

What is Dexcom Inc.'s P/E ratio?

Dexcom Inc.'s P/E ratio is 35.2.

Dexcom Inc.

NASDAQ · DXCM
$75.37+0.12(+0.16%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Dexcom Inc.'s future dividend policy...
Alpha Chat Insight

Dexcom Inc. trades at a P/E of 35.2 (premium valuation) with strong ROE of 34.5%. 3Y revenue CAGR of 17.0% highlights clear growth momentum.

Ask for details

Company Overview

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.

CEOMr. Jacob Steven Leach
SectorHealthcare
IndustryMedical Devices
Employees10,200

Company Statistics

FY 2025

Profile

$29.41BMarket Cap
$4.66BRevenue
0.00Shares Out
10,200Employees

Margins

60.10%Gross
29.14%EBITDA
19.56%Operating
23.35%Pre-Tax
17.94%Net

Valuation

35.17P/E
10.71P/B
6.31EV/Sales
22.00EV/EBITDA
27.30P/FCF

Growth (CAGR)

17.01%Rev 3Yr
19.33%Rev 5Yr
32.59%Op Inc 3Yr
24.94%Op Inc 5Yr
34.83%Net Inc 3Yr
11.12%Net Inc 5Yr

Returns

13.04%ROA
34.50%ROE
17.26%ROIC

Financial Health

$917.70MCash & Cash Equivalents
$2.68BNet Debt
130.88%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dexcom Inc. (ticker: DXCM) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 10,200 employees. Market cap is $29.4B.

The current price is $75.37 with a P/E ratio of 35.17x and P/B of 10.71x.

ROE is 34.50% and operating margin is 19.56%. Annual revenue is $4.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dexcom Inc. (DXCM) Stock Forecast 2026 $75.37 — Price, Financials & Analyst Targets | Alpha Lenz